NCT06692166View on ClinicalTrials.gov

A Study to Evaluate 9MW2821 Versus Treatment of Physician's Choice for Subjects With Recurrent or Metastatic Cervical Cancer

PHASE3RecruitingINTERVENTIONAL
Enrollment

420

Participants

Timeline

Start Date

September 10, 2024

Primary Completion Date

December 9, 2027

Study Completion Date

December 31, 2029

Conditions
Cervical Cancer
Interventions
DRUG

9MW2821

1.25mg/kg of 9MW2821 by intravenous infusion on days 1, 8 and 15 of every 28-day cycle

DRUG

Chemotherapy

1.0 or 1.25 mg/m \^2 topotecan by intravenous infusion on days 1 to 5 or 1000 mg/m \^2 gemcitabine by intravenous infusion on days 1 and 8 or 500 mg/m \^2 pemetrexed by intravenous infusion on day 1 of every 21 days

Trial Locations (2)

Unknown

RECRUITING

Cancer Hospital Chinese Academy of Medical Sciences, Beijing

RECRUITING

Fudan University Shanghai Cancer Center, Shanghai

All Listed Sponsors
lead

Mabwell (Shanghai) Bioscience Co., Ltd.

INDUSTRY